EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
Maximus, Inc.
EL7 Factor Analysis
How we score this
Overall71
Strong — clearly above market medianContrarianF 8/9Grey zoneBetter than 71% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
95
8.5x▲17.8xTop tier
▸
Growth
49
-3.3%▼7.1%Around median
▸
Quality
71
13.1%▲4.5%Top tier
▸
Safety
65
2.3x▲2.6xAround median
▸
Capital Return
70
2.20%▲2.12%Top tier
▸
Momentum
8
-32.4%▼2.9%Bottom tier
▸
Sentiment
50
2▼3Around median
MMS

MMS Maximus, Inc.

Maximus, Inc. · NYSE
Market Closed
56.92
▲ ⁦+0.69%⁩ (+0.39)
Market Cap$3.0B
Beta0.59
52w Low52w High
52.73100.00
Last Week
⁦-1.16%⁩
Last Month
⁦+2.93%⁩
Last 3 Months
⁦-8.83%⁩
Last Year
⁦-35.11%⁩
Fair Value
Low confidenceCurrent price$57
Analyst target · 2 analysts
$110
⁦+93%⁩
See it clearly undervalued
Range ⁦$110–$110⁩
vs
DCF (estimate)
$123
⁦+117%⁩
Sees it clearly undervalued
⁦7.9⁩% discount · ⁦2⁩% growth
Bottom lineThe two methods broadly agree — estimate range ⁦$110–$123⁩.

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener
Premium content

Get Your Premium Account Now

  • Stock Deep Analysis
  • The Advanced News Platform
Recommended
Annual plan
$17/mo
Monthly plan
$29/mo

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 2 analysts setting price target
$110.00
⁦+93.3%⁩
Current Price $56.92·Median $110.00
Low
$110.00
High
$110.00
Street summary

Stability of Maximus Price Targets Amid Broader Coverage

Price targets have not changed over the last 30 days; consensus remained at 110, with the high, low, and median all matching at the same level. Compared with the current price of 56.11, the gap between the price and the target remains substantial, but the data show no new target revision or divergence among estimates. The number of analysts increased from one to two in just the last day, broadening the coverage base without changing the consensus level.

As of 2026-09-09
Revisions momentum · 30d
⁦0.0%⁩
Average rating
★ 5.00
Strong Buy
Analyst coverage
⁦2 (+1)⁩
New coverage
Buy conviction
100%
High
Target dispersion
0%
Analyst ratings over time2 analysts rating
2
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months5.00 → 5.00
Recent analyst moves
  • ⬆ Upgrade2025-01-02
    Raymond James
    Outperform
  • = Reiterate2024-05-09
    Stifel Nicolaus
    —· $110.00
  • = Reiterate2024-03-20
    Stifel Nicolaus
    —· $105.00
Premium content
Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
MetricValuePosition within sectorVerdict
  • P/E (TTM)
    8.47x
    5.69x45.54x
    Very cheap
  • Forward P/E
    6.19x
    4.57x36.58x
    Very cheap
  • EV / EBITDA
    6.52x
    3.43x27.47x
    Very cheap
  • FCF Yield
    14.5%
    -32.7%11.5%
    Exceptional
  • Revenue Growth YoY
    -3.3%
    -10.7%43.4%
    Below average
  • EPS Growth YoY
    23.5%
    -128.3%132.7%
    Above average
  • Gross Margin
    25.6%
    8.6%54.6%
    Near median
  • ROIC
    13.1%
    -25.3%19.6%
    Strong
  • Net Debt / EBITDA
    2.35x
    0.55x4.37x
    Near median
  • Dividend Yield
    2.2%
    0.1%4.8%
    Moderate
  • Payout Ratio
    18.4%
    6.6%80.8%
    Low
  • Altman Z-Score
    2.94
    -5.667.97
    Above average
Financial Analysis
|

Stock Analysis

AI-generated
Based on 2026-08-06 data

Company Overview

Maximus manages technology-enabled government programs and services in the United States and abroad, generating revenue by executing contracts that support federal agencies, state programs, and clinical and employment services. The business is divided into three segments: U.S. Federal Services, U.S. Services, and Outside the U.S., with a clear concentration in federal operations. The company also invests in artificial intelligence tools and process improvements, including IVR, chatbots, and proactive outreach, to increase efficiency and improve the beneficiary experience.

In Q3 fiscal 2026, Maximus recorded revenue of $1.28 billion, while its EDGAR filings showed gross profit of $348.8 million, net income of $103.6 million, and earnings per share of $1.95. Gross profit was approximately 27% of revenue, while the adjusted EBITDA margin was 15.0% and adjusted earnings per share were $2.22, compared with a margin of 14.7% and adjusted earnings of $2.16 in the corresponding quarter of the previous year. On a trailing-twelve-month basis ending in fiscal 2026, revenue totaled $5.2 billion, net income was $370.9 million, and earnings per share were approximately $6.99.

U.S. Federal Services accounted for approximately $721 million, or about 56% of Q3 fiscal 2026 revenue, and achieved an operating income margin of 18.6%. U.S. Services recorded revenue of $418 million and an operating margin of 10.8%, while Outside the U.S. generated revenue of $140 million and a limited operating profit of $1.2 million. This mix shows that profitability depends heavily on the federal segment, while the contribution from operations outside the United States remains modest.

What's Driving the Stock

  • Maximus lowered its adjusted earnings per share forecast for fiscal 2026 to a range of $7.90 to $8.20, with a midpoint of $8.05 that is $0.35 below the previous midpoint, following the suspension of performance incentives under the VA MDE contract effective July 1, 2026. The company expects the suspension to continue through December 31, 2026, making the contract's impact the strongest factor in the near-term earnings outlook.
Earnings callEDGAR filings30-day newsInsider activity

Automated analysis for informational purposes only — not investment advice.

  • The company reaffirmed its fiscal 2026 revenue guidance of $5.2 billion to $5.35 billion, but with a bias toward the low end, and set adjusted EBITDA margin guidance at approximately 13.7%. The forecast implies adjusted earnings per share of approximately $1.91 in Q4 fiscal 2026 at the midpoint of the annual range.
  • The sales opportunity pipeline totaled $50.4 billion as of June 30, 2026, including $2.9 billion of submitted proposals, $2.4 billion of proposals in preparation, and $45.1 billion of opportunities being pursued by the company. New work represented 57% of the pipeline, while U.S. Federal Services accounted for 55% of it, in addition to $1.35 billion of contracts that had been awarded but not yet signed.
  • Maximus expects U.S. Services to return to positive mid-single-digit organic growth in Q4 fiscal 2026, supported by beneficiary outreach and activities related to Medicaid programs. In SNAP, the company conducted more than 40 demonstrations of the Accuracy Assistant tool and held 150 client meetings, amid a national payment error rate of approximately 10.6% in fiscal 2025 compared with 10.9% in fiscal 2024.
  • Artificial intelligence requirements or evaluation criteria are included in approximately 75% to 80% of new bids and recompetes in the business pipeline. Artificial intelligence-based improvements across five contracts, including IVR, script optimization, chatbots, and proactive outreach, improved the operating margin of that group by 3.5 percentage points.
  • Since the beginning of fiscal 2025, Maximus has repurchased approximately 8.3 million shares, equivalent to about 14% of the shares outstanding at the beginning of the period. In Q3 fiscal 2026 alone, it purchased approximately 0.75 million shares for $50 million, with the full $400 million board authorization remaining available as of June 30, 2026.
  • Buying & Selling Case

    ▲ Buying Case4 pts

    • +In Q3 fiscal 2026, the company achieved an adjusted EBITDA margin of 15.0%, higher than 14.7% in the corresponding period, while adjusted earnings per share rose to $2.22 from $2.16 despite the absence of some disaster-response volumes and temporary increases in clinical volumes that supported the previous period.
    • +A $50.4 billion opportunity pipeline, together with $1.35 billion of awarded but unsigned contracts, provides a potential foundation for improved bookings and growth; management said the latter includes longer-term contracts and some deals that have cleared protest procedures.
    • +The expected turnaround in U.S. Services could support growth during Q4 fiscal 2026 and fiscal 2027, as Medicaid beneficiary outreach activities have begun increasing volumes across several existing contracts, while SNAP is generating tangible interest in the Accuracy Assistant tool.
    • +Results from five contracts show that the use of artificial intelligence delivered a 3.5-percentage-point improvement in the operating margin of the relevant group, alongside artificial intelligence-related requirements in 75% to 80% of new bids and recompetes. This gives Maximus an opportunity to combine greater efficiency in existing contracts with stronger competitiveness in government tenders.

    ▼ Selling Case6 pts

    • −U.S. Federal Services represents approximately 56% of Q3 fiscal 2026 revenue, and the suspension of incentives under the VA MDE contract alone reduced the midpoint of adjusted earnings per share guidance by $0.35. This reveals the sensitivity of earnings to the terms of a federal client and a major program, while the incentive structure in the successor contract remains unspecified in the available draft scope of work.
    • −Maximus lowered its adjusted earnings per share guidance for fiscal 2026 to $7.90–$8.20 and set its annual adjusted EBITDA margin at approximately 13.7% due to the suspension of VA MDE incentives. It also expects the federal segment to post an operating margin of between 14.5% and 15.0% in Q4 fiscal 2026, below the 18.6% recorded in Q3.
    • −Q3 fiscal 2026 revenue of $1.28 billion was affected by comparison with an earlier period that benefited from temporary disaster support and temporary increases in clinical volumes. Annual revenue guidance of $5.2–$5.35 billion is also trending toward the low end, indicating weaker sales momentum than the quarterly profitability picture suggests.
    • −The value of contracts signed from the beginning of fiscal 2026 through June 30 was only $1.25 billion, with a book-to-bill ratio of approximately 0.5 times over the twelve-month period. Management explained that procurement delays, scope adjustments, the cancellation of some opportunities, and an increase in bridge contracts and short-term extensions make the timing of converting the $50.4 billion business pipeline uncertain.
    • −Operating activities used $125 million of cash, and free cash flow recorded an outflow of $137 million in Q3 fiscal 2026, while days sales outstanding rose to 98 days because of administrative delays at a major federal client. Despite collecting approximately $245 million after June 30, 2026, total debt increased to $1.65 billion and net leverage rose to 2 times from 1.8 times in the previous quarter.
    • −

    Valuation

    The average analyst price target is $110, with both the highest and lowest targets matching at $110 and a consensus Buy rating; this target is 10% above the top of the 52-week range of $100, while the bottom of the range is $52.73. However, the narrow target range of a single figure reduces the diversity of valuation signals, and the optimism should be weighed against the $0.35 reduction in the midpoint of adjusted earnings per share guidance for fiscal 2026, weak sales, and the suspension of VA MDE incentives.

    BuyAnalyst target: $110(+93.3%)

    Figures in the text are as of 2026-08-31; the live price is shown at the top of the page.

    FAQ

    What prompted Maximus to lower its fiscal 2026 earnings forecast?

    The VA client temporarily suspended performance incentives and penalties under the VA MDE contract for all vendors effective July 1, 2026, to improve the review and verification of monthly invoices. Maximus therefore removed the Q4 fiscal 2026 incentive contribution and lowered the midpoint of adjusted earnings per share guidance by $0.35 to $8.05. The new guidance range is $7.90 to $8.20, while the company maintained revenue guidance of $5.2 billion to $5.35 billion with a bias toward the low end.

    How important is the VA MDE contract to Maximus's results?

    U.S. Federal Services generated revenue of $721 million and an operating income margin of 18.6% in Q3 fiscal 2026, making it the company's largest segment. According to management's explanation, VA MDE incentives contributed approximately $0.35 in earnings per share in each of the first three quarters of fiscal 2026. The company also assumes that incentives will not accrue in Q1 fiscal 2027, while the published draft scope of work included all six regions in which Maximus currently operates.

    Can Maximus's contract pipeline reaccelerate growth?

    The total sales opportunity pipeline was $50.4 billion as of June 30, 2026, including $2.9 billion of submitted proposals and $2.4 billion of proposals in preparation. The company also had $1.35 billion of contracts that had been awarded but not yet signed, compared with $1.25 billion of contracts signed since the beginning of fiscal 2026. However, the book-to-bill ratio was approximately 0.5 times over the twelve-month period, and the timing of awards remained exposed to procurement delays, protests, and adjustments to opportunity scopes.

    How does Maximus benefit from artificial intelligence?

    Artificial intelligence-related requirements or criteria were included in approximately 75% to 80% of new bids and recompetes in Maximus's business pipeline through Q3 fiscal 2026. Improvements including IVR, chatbots, and proactive outreach across five contracts delivered a 3.5-percentage-point improvement in the operating margin of the relevant group. Maximus Ventures also invested directly in Spectro Cloud, a platform for managing artificial intelligence infrastructure with a focus on cost, security, and governance.

    What opportunities does Maximus have in Medicaid and SNAP?

    The company expects U.S. Services to achieve mid-single-digit organic growth in Q4 fiscal 2026, driven by Medicaid beneficiary outreach activities under existing contracts. In SNAP, it conducted more than 40 demonstrations of the Accuracy Assistant tool and 150 client meetings, while the national payment error rate was approximately 10.6% in fiscal 2025 compared with 10.9% in fiscal 2024. However, management said Medicaid discussions progressed more slowly than expected because of the complexity of the interim rules and the need for states to determine implementation mechanisms.

    What is Maximus's liquidity and debt position?

    Operations used $125 million of cash, and free cash flow recorded an outflow of $137 million in Q3 fiscal 2026, with days sales outstanding reaching 98 days. After June 30, 2026, the company collected approximately $245 million from a major federal client and expects to end fiscal 2026 with days sales outstanding below 70 days and free cash flow of between $425 million and $475 million. Total debt was $1.65 billion at the end of the quarter, with net leverage of 2 times within the target range of 2 to 3 times.

    Medicaid and SNAP opportunities are tied to regulatory and implementation decisions by states, and Medicaid discussions progressed more slowly than management expected because of the complexity of the interim federal rule and uncertainty over the implementation of the requirements. The call also noted that a lawsuit challenged the implementation of work requirements, adding uncertainty to the timing and scale of business associated with these programs.